Company

Pioneering RNA-Targeted Small Molecule Therapeutics

Ribometrix is a preclinical biotechnology company leading efforts to deliver the full promise of small molecule therapeutics that directly target cellular RNAs. Our best-in-field drug discovery and development platform leverages proprietary, state-of-the art capabilities to target complex RNA structures, thereby modulating RNA function to correct disease-causing production of encoded proteins.

Ribometrix scientist
Ribometrix Lab

A Unique Drug Discovery Engine

Built on nearly a decade of proprietary advances, our platform combines the well-established power of small molecule drug discovery and development with best-in-field RNA-focused capabilities to realize the full potential of RNA targeting while avoiding the limitations of oligonucleotide-based modalities.

Our growing pipeline of preclinical programs leverages our game-changing RNA-adapted high throughput screening strategies, and our breakthrough ability to identify small molecules that correct disease-causing protein production solely through selective binding to the encoding mRNA. This core strategy is also complemented by the development of RNA-degrading add-ons for those cases where binding alone does not deliver modulation.

We believe our commitment to this new paradigm, driven by a unique platform that tailors the discovery strategy to each interventional opportunity, will deliver innovative new therapies to patients.

Ribometrix lab

Our History

In June 2016, Drs. Katie Warner and Kevin Weeks leveraged state-of-the-art capabilities in RNA structure determination to found Ribometrix Inc. on a big idea: to realize the huge and well-recognized therapeutic potential of targeting disease-causing mRNAs by using small molecule drugs that bind to their complex folded structures, thereby bypass the limitations of oligonucleotide-based approaches.

Working in the heart of North Carolina’s vibrant Research Triangle Park, the company’s dedicated team has since tackled what is invariably one of the most arduous challenges in our industry: that of establishing a new therapeutic modality.

Through the careful and focused application of multidisciplinary expertise to enable a myriad of scientific, technical and strategic advances, we have successfully built a proprietary preclinical platform for RNA-targeting drug discovery and development. Having matured our capabilities and know-how over generations of wholly-owned and partnered programs, we continue to learn, grow and discover with a single goal in mind: to improve the lives of patients with unmet medical needs.

Ribometrix team members
  • Our Mission

    Leveraging RNA expertise to discover and develop transformative small-molecule drugs.

  • Our Vision

    We are committed to improving the lives of patients and families by developing therapies through innovative science. 

  • Our Values

    Collaboration

    We seek help when we need it and provide support when we can.

    Integrity

    We act with respect, sincerity, and transparency.

    Innovation

    We create with intent.

    Empowerment

    We are accountable for our actions and results.

    Resilience

    We conquer with persistence and adaptability.

    Community

    We foster camaraderie with shared purpose, values, and goals.

Our People

Ribometrix Leadership & Team

Meet the Ribometrix team, where every individual is valued as part of a collaborative community sharing a common focus on advancing the field of modulating RNA biology to discover and develop transformative small-molecule drugs.

Ribometrix team meeting
Careers

Join Our Team

We are a team of individuals driven by the spirit of innovation, collaboration, empowerment, and integrity who are committed to the goal of helping patients with our novel therapeutic approach.

If you are looking for an opportunity to pioneer new science, collaborate with great people, and ultimately help those in need, then Ribometrix may be the place for you.

Questions about our research, platform, or opportunities? Let’s connect.